Cost-Effectiveness of Pyrotinib Plus Capecitabine versus Lapatinib Plus Capecitabine for the Treatment of HER2-Positive Metastatic Breast Cancer in China: A Scenario Analysis of Health Insurance Coverage.

Yuwen BaoZhuolin ZhangXuan HeLele CaiXiao WangXin Li

Published in: Current oncology (Toronto, Ont.) (2022)

Compared to lapatinib plus capecitabine, the pyrotinib plus capecitabine enrolled in NRDL is a cost-effective alternative second-line treatment for patients with HER2-positive metastatic BC in China.

Keyphrases

metastatic breast cancer
health insurance
phase ii study
squamous cell carcinoma
locally advanced
affordable care act
healthcare
clinical trial
randomized controlled trial
radiation therapy
combination therapy
study protocol